Drug Patents owned by Ferring

1. List of Firmagon drug patents

FIRMAGON's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9579359 FERRING Method of treating prostate cancer with GnRH antagonist
Feb, 2029

(5 years from now)

US10973870 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(5 years from now)

US10729739 FERRING Methods of treating prostate cancer with GnRH antagonist
Feb, 2029

(5 years from now)

US9415085 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(9 years from now)

US10695398 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(9 years from now)

Drugs and Companies using DEGARELIX ACETATE ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer

Dosage: POWDER;SUBCUTANEOUS

How can I launch a generic of FIRMAGON before it's patent expiration?
More Information on Dosage

FIRMAGON family patents

17

United States

12

Japan

8

Korea, Republic of

7

European Union

5

Hong Kong

4

New Zealand

4

China

4

EA

3

Portugal

3

Spain

3

Croatia

3

Cyprus

3

Slovenia

3

Poland

3

Denmark

2

Russia

2

Brazil

2

IB

2

Mexico

2

Taiwan, Province of China

2

Canada

2

Israel

2

Australia

1

Jordan

1

South Africa

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic